January 23, 2023 10:09 AM ESTUpdated February 7, 09:37 AM

#JPM23: When will the IPO win­dow open? What terms are star­tups get­ting? Here's what to ex­pect from cap­i­tal mar­kets this year

Drew Armstrong

Executive Editor

Ex­ec­u­tive Ed­i­tor Drew Arm­strong sat down with Bay­er’s busi­ness de­vel­op­ment leader Mar­i­anne De Backer, PwC’s phar­ma deals chief Roel Van den Akker, and Sofinno­va In­vest­ments …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times